Carmignac strengthens equity investment team with senior healthcare analyst appointment

  • Published

Carmignac has strengthened its equity investment team with the appointment of Rosie Turner as a senior healthcare analyst, reinforcing its expertise in this sector.


Rosie Turner joins Carmignac from Jefferies where she had a senior vice president position on the sell side research covering the healthcare sector. She has previously worked at Barclays Capital from 2014 to 2022 covering global healthcare companies. She started her career in 2008 at UBS Investment Bank in the global equity sales team with a focus on analysing the healthcare and luxury sectors. Rosie holds an Economics BA from Durham University.

Carmignac’s investment team comprises 58 fund managers and analysts with 34 nationalities. Led by David Older, the equity investment team consists of 20 experts in European, emerging market, global and thematic equities. Fund managers are supported by dedicated and experienced sector specialists, enriching the investment process through their in-depth analysis and conviction, as well as an entrepreneurial mindset geared towards today’s fast-paced and evolving capital markets. The strength of the team lies in their ability to capitalize on global secular trends through a stock-specific, bottom-up approach which is supported by the firm’s top-down macro analysis and strict risk-management process.

Rosie is based in London and reports to David Older.

David Older, head of equities at Carmignac comments: “Healthcare has always been a strong investment conviction as the sector abounds with innovative, secular growth companies across diversified sub-segments. Rosie’s appointment adds significant experience in the healthcare sector to our equity team. Her strong expertise will reinforce our investment team’s ability to access promising and disruptive opportunities with high conviction in this fast-evolving sector.”

Thank you for taking the time to provide your feedback, appreciated.